日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Prognostic significance of tumor fraction in advanced sarcoma: highlighting a novel circulating biomarker

肿瘤分数在晚期肉瘤预后中的意义：一种新型循环生物标志物的发现

期刊:Clinical and Experimental Medicine
影响因子:3.5
doi:10.1007/s10238-026-02069-8
Taleb, Sofiane; Brunet, Maxime; Belcaid, Laila; Bahleda, Ratislav; Verret, Benjamin; Cesne, Axel Le; Peyraud, Florent; Spalato-Ceruso, Mariella; Toulmonde, Maud; Italiano, Antoine
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Phospho-Switch: Regulation of the Activity of SAM-Dependent Methyltransferases Using H-Phosphinic SAM Analogue

磷酸开关：利用H-膦酸SAM类似物调节SAM依赖性甲基转移酶的活性

期刊:International Journal of Molecular Sciences
影响因子:4.9
doi:10.3390/ijms26178590
Filonov, Vsevolod L; Khomutov, Maxim A; Rudenko, Alexander Yu; Mariasina, Sofia S; Ozhiganov, Ratislav M; Sergeev, Alexander V; Kochetkov, Sergei N; Polshakov, Vladimir I; Gromova, Elizaveta S; Khandazhinskaya, Anastasia L; Khomutov, Alex R
发表日期：2025
文献求助 收藏

Organophosphorus S-adenosyl-L-methionine mimetics: synthesis, stability, and substrate properties

有机磷S-腺苷-L-蛋氨酸类似物：合成、稳定性及底物性质

期刊:Frontiers in Chemistry
影响因子:4.2
doi:10.3389/fchem.2024.1448747
Rudenko, Alexander Yu; Mariasina, Sofia S; Bolikhova, Anastasiia K; Nikulin, Maxim V; Ozhiganov, Ratislav M; Vasil'ev, Vasiliy G; Ikhalaynen, Yuri A; Khandazhinskaya, Anastasia L; Khomutov, Maxim A; Sergiev, Peter V; Khomutov, Alex R; Polshakov, Vladimir I
发表日期：2024
文献求助 收藏

Self-Reported Mental Health and Lifestyle Behaviour During the COVID-19 Pandemic in the Czech Population: Evidence From Two Cross-Sectional Surveys

捷克人群在新冠疫情期间的自我报告心理健康状况和生活方式行为：来自两项横断面调查的证据

期刊:International Journal of Public Health
影响因子:2.4
doi:10.3389/ijph.2022.1604395
Dalecká, Andrea; Tomášková, Hana; Šlachtová, Hana; Skýbová, Dagmar; Mad'ar, Ratislav
微生物学
新冠
发表日期：2022
文献求助 收藏

Phase I dose-escalation study of pilaralisib (SAR245408, XL147), a pan-class I PI3K inhibitor, in combination with erlotinib in patients with solid tumors

一项针对实体瘤患者的 pilaralisib（SAR245408，XL147，一种泛 I 类 PI3K 抑制剂）联合厄洛替尼的 I 期剂量递增研究

期刊:Oncologist
影响因子:4.2
doi:10.1634/theoncologist.2014-0449
Soria, Jean-Charles; LoRusso, Patricia; Bahleda, Ratislav; Lager, Joanne; Liu, Li; Jiang, Jason; Martini, Jean-François; Macé, Sandrine; Burris, Howard
发表日期：2015
文献求助 收藏

A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.

一项针对骨髓纤维化患者的 JAK2 抑制剂 AZD1480 的 I 期、开放标签、多中心研究

期刊:Leukemia Research
影响因子:2.2
doi:10.1016/j.leukres.2014.11.018
Verstovsek Srdan, Hoffman Ronald, Mascarenhas John, Soria Jean-Charles, Bahleda Ratislav, McCoon Patricia, Tang Weifeng, Cortes Jorge, Kantarjian Hagop, Ribrag Vincent
骨科研究
发表日期：2015
文献求助 收藏

Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate

一项针对难治性癌症患者的I期临床试验，将甲磺酸伊马替尼与IL-2联合使用：IL-2会干扰甲磺酸伊马替尼的药代动力学。

期刊:Oncoimmunology
影响因子:6.3
doi:10.4161/onci.23079
Pautier, Patricia; Locher, Clara; Robert, Caroline; Deroussent, Alain; Flament, Caroline; Le Cesne, Axel; Rey, Annie; Bahleda, Ratislav; Ribrag, Vincent; Soria, Jean-Charles; Vassal, Gilles; Eggermont, Alexander; Zitvogel, Laurence; Chaput, Nathalie; Paci, Angelo
肿瘤
IL-2
肿瘤免疫
发表日期：2013
文献求助 收藏